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a cBACKGROUND Omecamtiv mecarbil (OM) is a selective cardiac myosin activator that increases myocardial function in
healthy volunteers and in patients with chronic heart failure.
OBJECTIVES This study evaluated the pharmacokinetics, pharmacodynamics, tolerability, safety, and efficacy of OM in
patients with acute heart failure (AHF).
METHODS Patients admitted for AHF with left ventricular ejection fraction #40%, dyspnea, and elevated plasma
concentrations of natriuretic peptides were randomized to receive a double-blind, 48-h intravenous infusion of placebo
or OM in 3 sequential, escalating-dose cohorts.
RESULTS In 606 patients, OM did not improve the primary endpoint of dyspnea relief (3 OM dose groups and pooled
placebo: placebo, 41%; OM cohort 1, 42%; cohort 2, 47%; cohort 3, 51%; p ¼ 0.33) or any of the secondary outcomes
studied. In supplemental, pre-specified analyses, OM resulted in greater dyspnea relief at 48 h (placebo, 37% vs. OM,
51%; p ¼ 0.034) and through 5 days (p ¼ 0.038) in the high-dose cohort. OM exerted plasma concentration-related
increases in left ventricular systolic ejection time (p < 0.0001) and decreases in end-systolic dimension (p < 0.05).
The adverse event profile and tolerability of OM were similar to those of placebo, without increases in ventricular or
supraventricular tachyarrhythmias. Plasma troponin concentrations were higher in OM-treated patients compared with
placebo (median difference at 48 h, 0.004 ng/ml), but with no obvious relationship with OM concentration (p ¼ 0.95).
CONCLUSIONS In patients with AHF, intravenous OM did not meet the primary endpoint of dyspnea improvement, but
it was generally well tolerated, it increased systolic ejection time, and it may have improved dyspnea in the high-dose
group. (Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure [ATOMIC-AHF];
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AB BR E V I A T I O N S
AND ACRONYM S
AHF = acute heart failure
BNP = B-type natriuretic
peptide
BP = blood pressure
CEC = clinical events
committee
CHF = chronic heart failure
cTn = cardiac troponin
cTnI = cardiac troponin I
EF = ejection fraction
ESD = end-systolic dimension
HF = heart failure
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1445T he morbidity and mortality associated withacute heart failure (AHF) remain substantialwith few therapeutic advances in recent de-
cades, a finding suggesting that new AHF therapies
represent a major unmet medical need (1). Although
AHF is a heterogeneous condition, impaired cardiac
contractility is a central pathophysiological feature in
at least one-half of these patients and may be a key
therapeutic target. However, trials of many inotropic
agents have failed to demonstrate either efficacy or
safety because of adverse effects such as arrhythmias,
hypotension,myocardial ischemia, and increasedmor-
tality (2); consequently, recent guidelines limit the use
of these agents to patients with cardiogenic shock or
evidence of marked end-organ hypoperfusion (3,4).SEE PAGE 1456
IV = intravenous
LV = left ventricular
OM = omecamtiv mecarbil
PD = pharmacodynamics
PK = pharmacokinetics
SET = systolic ejection
SVT = supraventricular
tachyarrhythmia
VT = ventricular
arrhythmiaOmecamtiv mecarbil (OM) is a selective small
molecule activator of cardiac myosin that prolongs
myocardial systole (5). In contrast to traditional ino-
tropes, which increase myocardial contraction rate
and shorten systole duration, OM increases stroke
volume by extending the duration of systole without
changing the velocity of myocardial contraction (i.e.,
no change in pressure with respect to time, þdP/dt). In
pre-clinical models, OM increased cardiac contractility
and stroke volume without apparent effects on
myocardial oxygen demand (6) or cardiac myocyte
calcium transients (5), which are putative mechanisms
of harm for traditional inotropic agents, such as
beta-agonists and phosphodiesterase-3 inhibitors. In
healthy volunteers (7) and in patients with chronic
heart failure (CHF) and systolic dysfunction (8), OM
increased stroke volume and cardiac output while
decreasing heart rate. In the ATOMIC-AHF (Acute
Treatment with Omecamtiv Mecarbil to Increase
Contractility in Acute Heart Failure; NCT01300013)
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METHODS
ATOMIC-AHF was a prospective, phase II,
randomized, double-blind, placebo-con-
trolled, dose-escalation, sequential-cohort
trial comparing OM with placebo in patients
hospitalized for AHF. Patients were enrolled
from 106 centers in Europe, Australia, and
North America. Each participating center’s
Institutional Review Board approved the
study, and all participants provided written
informed consent. The executive committee
was responsible for the trial design, and
the national leaders supervised patient
recruitment and clinical management of the
trial. An independent data monitoring com-
mittee regularly reviewed unblinded data
prepared by an external biostatistical group.
An independent clinical events committee
(CEC) (Duke Clinical Research Institute,
Durham, North Carolina) adjudicated deaths,
rehospitalizations, and major cardiovascular events.
We vouch for the completeness and accuracy of the
data and the analyses as well as the fidelity of the study
to the protocol.
PATIENTS. We enrolled men and women 18 through
85 years of age with a history of CHF and left ven-
tricular (LV) ejection fraction (EF) #40%, who were
admitted for AHF and had dyspnea at rest or with
minimal exertion and had increased plasma concen-
trations of B-type natriuretic peptides (BNPs):
BNP $400 pg/ml or N-terminal (NT)-proBNP $1,600
pg/ml; BNP $600 pg/ml or NT-proBNP $2,400 pg/ml
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1446dyspnea 2 h after receipt of at least 40 mg of IV
furosemide (or an equivalent dose of an alternative
loop diuretic) and were randomized within 24 h of
their initial IV dose of loop diuretic (the initial portion
of cohort 1 required randomization within 16 h of
presentation, after which the protocol was amended
to allow enrollment out to 24 h after first diuretic
dose). Patients receiving IV inotropic agents (other
than dopamine #5 mg/kg/min) were excluded. Other
major exclusions were acute coronary syndrome
within 30 days, blood pressure (BP) >160/100 mm Hg,
systolic BP <90 mm Hg, heart rate <60 or >110
beats/min, estimated glomerular filtration rate calcu-
lated by the Modification of Diet in Renal Disease
equation <20 ml/min/1.73 m2 during screening, severe
pulmonary disease, and significant stenotic valvular
disease.
Subjects were centrally randomized 1:1 to IV OM or
matching placebo within each cohort. Randomization
through an interactive voice response system was
stratified by geographic region (North America and
Australia vs. rest of the world) and by planned
participation in the PK/PD substudy.
PROCEDURES. ATOMIC-AHF enrolled 3 sequential
cohorts (w200 patients per cohort) (Online Figure 1)
targeting mean OM plasma concentrations at 48 h of
115 ng/ml, 230 ng/ml, and 310 ng/ml and using 3 esca-
lating dose regimens (Online Appendix). As specified
by protocol, enrollment was paused between cohorts
to allow for a data monitoring committee safety data
review; enrollment resumed on the committee’s
recommendation. Through PK/PD modeling, these
doses were designed to attain progressively higher
target plasma concentrations, with the low dose
anticipated to have minimal cardiac effect, an inter-
mediate dose, and the high dose chosen to maximize
the PD response andminimize occurrence of excessive
plasma concentrations in most patients (>99%).
Patients received OM or placebo infused over 48 h and
had to remain hospitalized for at least 24 h after
infusion termination (Online Figure 2). Patients were
evaluated in person during hospitalization and on day
30 and by telephone at 6 months for vital status.
OUTCOMES. The primary efficacy endpoint evalu-
ated dyspnea improvement using a patient-reported
7-level Likert scale. A responder was defined as a
patient with minimally, moderately, or markedly
improved dyspnea by 6 h after the start of infusion
and moderately or markedly improved dyspnea at 24
and 48 h, without experiencing worsening heart
failure (HF) or death from any cause by 48 h. Wors-
ening HF was defined as worsening symptoms or
signs of HF necessitating initiation, reinstitution, orintensification of IV or mechanical HF treatment.
Secondary and exploratory endpoints included other
evaluations of symptoms and clinical events (Online
Appendix).
Patients in sinus rhythm could participate in a
PK/PD substudy that provided additional PK data
through supplementary blood sampling and explored
the relationship between OM plasma concentrations
and select echocardiographic measurements. Echo-
cardiograms were obtained at baseline, 24 h, and 48 h.
ATOMIC-AHF used standardized, intensive serial
monitoring of cardiac troponin (cTn) plasma concen-
trations in all patients by means of a sensitive cardiac
troponin I (cTnI) assay (Siemens ADVIA Centaur
TnI-Ultra, Siemens Healthcare GmbH, Erlangen,
Germany; 10% coefficient of variation ¼ 0.03 ng/ml,
99th percentile upper reference limit ¼ 0.04 ng/ml)
(9). Samples were obtained at baseline and again at
the following times: 4, 15, 24, 48, 72 h; day 5 or day of
discharge; and day 30 after study drug initiation.
The CEC adjudicated all rehospitalizations, deaths,
and cases of potential myocardial infarction or
ischemia. A CEC review for potential myocardial
ischemia or infarction could be triggered by either the
investigators or the CEC through clinical evidence of
an event (e.g., chest pain, electrocardiogram changes)
or by pre-specified changes in cTnI (>0.04 ng/ml in
patients without previously detectable cTnI or an
increase in cTnI >0.03 ng/ml in patients with previ-
ously detectable cTnI). Adverse events and serious
adverse events were recorded through day 30.
STATISTICAL ANALYSIS. All analyses were per-
formed in patients who received at least 1 dose of
investigational product. The planned sample size of
600 patients provided 88% power to detect superi-
ority of 1 of the OM doses over placebo for the primary
endpoint of dyspnea response, assuming response
rates of 23% and 40% in the placebo and OM groups,
respectively (10,11). See the Online Appendix for
additional details.
RESULTS
From May 2011 to April 2013, 613 patients were
enrolled in ATOMIC-AHF from 106 centers in 19
countries, and 606 patients received investigational
product (Online Figure 3). Patients enrolled in this
study (Table 1) had a mean age of 66  11 years and
were predominantly white (88%) and male (77%) with
multiple comorbidities. Before the index admission,
most patients were receiving guideline-recommended
pharmacological therapy for chronic symptomatic HF
(>80% New York Heart Association functional class II
to III). Investigators attributed the cause of HF to
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1447coronary artery disease in 62% of patients, and mean
LVEF was 26  8%. At baseline, most patients also
had impaired renal function, elevated troponin, and
raised plasma NT-proBNP concentrations. Some het-
erogeneity among treatment groups was evident
despite randomization; for example, more patients
assigned toOMhad elevated troponins (median pooled
placebo, 0.044 ng/ml; pooled OM, 0.054 ng/ml).
Additionally, differences in baseline characteristics
emerged among the cohorts over time during the
2-year enrollment period, including increasing
enrollment from Eastern European sites, decreasing
nonwhite representation, fewer patients hospitalized
for HF within the 12 months before enrollment, and
greater baseline troponin concentrations. A protocol
amendment resulted in a longer time from first
diuretic dose to randomization in the later cohorts
compared with the first cohort.
EFFICACY EVALUATION. The response rates of the
primary endpoint of dyspnea relief within 48 h among
the placebo groups of the 3 cohorts were not statisti-
cally different (p ¼ 0.316). Therefore, as specified in
the protocol, the pooled placebo group was used for
the statistical analysis of the primary endpoint. The
global test of dyspnea relief response rate was similar
among the 3 individual OM cohorts and did not differ
from the pooled placebo group (p ¼ 0.331), although
the response rate did improve numerically with
increasing OM dose (Central Illustration, panel A).
Thus, the primary endpoint was not achieved.
However, as noted earlier, because of the months-
long time delays among cohorts for data monitoring
committee reviews, differences in time to randomiza-
tion, region of enrollment, and baseline characteristics
were observed among the cohorts, so a pre-specified
supplemental analysis of comparisons between pla-
cebo andOM groupswithin each cohort was performed
(Central Illustration, panel B). Cohort 3 had a 41%
relative improvement in dyspnea relief at 48 h (14%
absolute difference: placebo 37%, OM 51%; nominal
p ¼ 0.034). An exploratory post hoc logistic regression
analysis across all cohorts demonstrated greater dys-
pnea response rates with higher total dose (response
rate ratio per 50 mg increase in OM dose: 1.06, 95%
confidence interval [CI]: 1.01 to 1.11; p¼0.025 adjusting
for region, cohort, age, baseline dyspnea numeric
rating scale, and duration between presentation and
randomization as covariates; p ¼ 0.035 unadjusted) or
with increased OM exposure integrated as the area
under the curve of OM plasma concentrations
(response rate ratio per increase of 4,000 h$ng/ml in
the area under the curve at 48 h: 1.06; 95% CI: 1.02 to
1.11; p ¼ 0.007 adjusted; p ¼ 0.016 unadjusted).There were no statistically significant differences
for any of the secondary endpoints when OM treat-
ment cohorts were compared with the pooled placebo
(Table 2). However, analysis of the dyspnea numeric
rating scale area under the curve through day 5 noted
increased dyspnea improvement in cohort 3 OM-
treated patients compared with its matching placebo
group (nominal p ¼ 0.038), a finding supporting
potential symptom improvement in the highest-dose
cohort. The incidence of death or worsening HF
through day 7 was driven primarily by worsening HF
events, with numerically fewer events in patients
assigned to OM within each cohort.
The exploratory endpoints of global rank score,
total IV loop diuretic use, CHF medication at dis-
charge, and health resource use were similar between
the OM and placebo groups. Supraventricular tachy-
arrhythmia (SVT) requiring treatment from baseline
to discharge occurred in 12 placebo-treated subjects
and 3 OM-treated subjects, whereas ventricular
tachyarrhythmia (VT) requiring treatment occurred in
2 patients treated with placebo and 4 OM-treated
patients. Renal impairment (defined as creatinine
increase $0.3 mg/dl or $25% from baseline at day 5
or discharge) occurred in 52 (17.2%) patients
who received placebo compared with 36 (11.9%)
OM-treated subjects. Within each cohort, numerically
fewer patients assigned to OM developed renal
impairment than did those assigned to placebo,
although this difference did not attain statistical
significance (Online Figure 4).
PHARMACOKINETICS AND PHARMACODYNAMICS.
The 3 dosing regimens targeted OM mean plasma
concentrations at 48 h (C48) of 115, 230, and 310 ng/ml.
The actual measured C48 for the respective cohorts
were mean 148  49 ng/ml, 311  115 ng/ml, and
425 173 ng/ml. There was a concentration-dependent
reduction in heart rate (p < 0.0001) and an increase in
BP (p ¼ 0.0017) from baseline with OM relative
to placebo (Table 3). The echocardiographic substudy
enrolled 89 of the planned 240 subjects and showed
that OM caused plasma concentration–dependent
increases in LV systolic ejection time (SET)
(p < 0.0001) (Figure 1). The mean placebo-corrected
increase in SET was 23, 34, and 53 ms for OM
concentration ranges of 88 to 200 ng/ml, 201 to 300
ng/ml, and >300 ng/ml, respectively (p < 0.005 for the
difference from placebo for all ranges). There was
also a significant concentration-related decrease
in left ventricular end-systolic dimension (LVESD)
(p < 0.05).
SAFETY AND TOLERABILITY. Of the 606 patients
who received infusions, 92% (281 of 303) of patients
TABLE 1 Baseline Characteristics
Pooled Cohort 1 Cohort 2 Cohort 3
Placebo
(n ¼ 303)
OM
(n ¼ 303)
Placebo
(b ¼ 103)
OM
(n ¼ 103)
Placebo
(n ¼ 99)
OM
(n ¼ 99)
Placebo
(n ¼ 101)
OM
(n ¼ 101)
Demographics
Age, yrs 66  11 66  11 65  13 65  12 66  10 66  10 66  10 68  11
Male 230 (75.9) 236 (77.9) 81 (78.6) 78 (75.7) 69 (69.7) 81 (81.8) 80 (79.2) 77 (76.2)
Race
White 270 (89.1) 260 (85.8) 87 (84.5) 87 (84.5) 91 (91.9) 82 (82.8) 92 (91.1) 91 (90.1)
Nonwhite 33 (10.9) 43 (14.2) 16 (15.5) 16 (15.5) 8 (8.1) 17 (17.2) 9 (8.9) 10 (9.9)
Region
Eastern Europe 160 (52.8)* 164 (54.1) 41 (39.8) 46 (44.7) 59 (59.6) 55 (55.6) 60 (59.4) 63 (62.4)
Western Europe 62 (20.5)* 58 (19.1) 24 (23.3) 19 (18.5) 15 (15.2) 19 (19.2) 23 (22.8) 20 (19.8)
United States/Canada/Australia 81 (26.7)* 81 (26.7) 38 (36.9) 38 (36.9) 25 (25.3) 25 (25.3) 18 (17.8) 18 (17.8)
Heart failure history
Ischemic heart disease 189 (62.4) 189 (62.4) 66 (64.1) 64 (62.1) 56 (56.6) 58 (58.6) 67 (66.3) 67 (66.3)
Years from HF diagnosis 5.7  5.5 5.9  5.4 6.3  6.3 6.3  6.2 5.1  4.8 5.6  5.0 5.5  5.3 5.8  5.0
NYHA functional class before decompensation
I 9 (3.0) 6 (2.0) 5 (4.9) 4 (3.9) 4 (4.0) 2 (2.0) 0 (0.0) 0 (0.0)
II 97 (32.2) 89 (29.4) 28 (27.2) 27 (26.2) 27 (27.3) 26 (26.3) 42 (42.4) 36 (35.6)
III 153 (50.8) 151 (49.8) 52 (50.5) 53 (51.5) 54 (54.5) 52 (52.5) 47 (47.5) 46 (45.5)
IV 42 (14.0) 57 (18.8) 18 (17.5) 19 (18.4) 14 (14.1) 19 (19.2) 10 (10.1) 19 (18.8)
Hospitalized for AHF in past 12 months 157 (52)* 169 (56) 65 (63) 64 (62) 53 (54) 59 (60) 39 (39) 46 (46)
Most recent LVEF, % 26  8 26  8 26  7 26  8 26  8 25  7 28  8 28  7
Selected comorbidities
Previous MI 146 (48.5) 161 (53.1) 58 (57.4) 55 (53.4) 41 (41.4) 48 (48.5) 47 (46.5) 58 (57.4)
Persistent AF or flutter 100 (33.0) 98 (32.3) 27 (26.2) 30 (29.1) 41 (41.4) 32 (32.3) 32 (31.7) 36 (35.6)
Paroxysmal AF or flutter 62 (20.5)* 70 (23.1) 29 (28.2) 20 (19.4) 18 (18.2) 26 (26.3) 15 (14.9) 24 (23.8)
Diabetes mellitus 136 (44.9) 133 (43.9) 43 (41.7) 50 (48.5) 47 (47.5) 41 (41.4) 46 (45.5) 42 (41.6)
Hypertension 244 (80.5) 249 (82.2) 80 (77.7) 86 (83.5) 81 (81.8) 80 (80.8) 83 (82.2) 83 (82.2)
Dyslipidemia 175 (57.8) 170 (56.1) 63 (61.2) 61 (59.2) 59 (59.6) 58 (58.6) 53 (52.5) 51 (50.5)
Previous transient ischemic attack 19 (6.3) 12 (4.0) 4 (3.9) 3 (2.9) 8 (8.1) 6 (6.1) 7 (6.9) 3 (3.0)
Prior stroke 35 (11.6) 39 (12.9) 11 (10.7) 11 (10.7) 14 (14.1) 15 (15.2) 10 (9.9) 13 (12.9)
Peripheral artery disease 47 (15.5) 40 (13.2) 18 (17.5) 18 (17.5) 16 (16.2) 10 (10.1) 13 (12.9) 12 (11.9)
Chronic obstructive pulmonary disease 68 (22.4) 76 (25.1) 24 (23.3) 28 (27.2) 22 (22.2) 21 (21.2) 22 (21.8) 27 (26.7)
Selected baseline outpatient medications
Diuretics 270 (89.1)* 270 (89.1) 95 (92.2) 90 (87.4) 94 (94.9) 91 (91.9) 81 (80.2) 89 (88.1)
ACE inhibitors/angiotensin receptor blockers 237 (78.2) 239 (78.9) 84 (81.6) 81 (78.6) 74 (74.7) 73 (73.7) 79 (78.2) 85 (84.2)
Beta-blocker 261 (86.1)* 270 (89.1) 94 (91.3) 93 (90.3) 88 (88.9) 86 (86.9) 79 (78.2) 91 (90.1)
Digoxin 70 (23.1) 86 (28.4) 20 (19.4) 33 (32.0) 28 (28.3) 29 (29.3) 22 (21.8) 24 (23.8)
Mineralocorticoid receptor antagonist 168 (55.5) 173 (57.1) 56 (54.4) 56 (54.4) 58 (58.6) 58 (58.6) 54 (53.5) 59 (58.4)
Ivabradine 8 (2.6) 14 (4.6) 3 (2.9) 4 (3.9) 3 (3.0) 4 (4.0) 2 (2.0) 6 (5.9)
Statins 168 (55.5) 159 (52.5) 58 (56.3) 53 (51.5) 50 (50.5) 51 (51.5) 60 (59.4) 55 (54.5)
Continued on the next page
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1448assigned to placebo and 93% (282 of 303) assigned to
OM completed 48 h; the mean duration of infusion
was similar across all groups. There were 191 (63%)
patients reporting any adverse event in the placebo
group compared with 177 (58%) in the OM group
(Table 4). Rates for serious adverse events were
similar in patients assigned to placebo (n ¼ 70; 23%)
and OM (n ¼ 66; 22%).
All-cause rehospitalizations (placebo: n ¼ 47,
15.5%; OM: n ¼ 39, 12.9%) and rehospitalizations for
HF (placebo: n ¼ 19, 6.3%; OM: n ¼ 22, 7.3%) within
30 days were similar between pooled OM andplacebo. There were 10 deaths (3.3%) within 30 days
in patients assigned to placebo versus 8 (2.6%) in
patients assigned to OM; all causes of death were
cardiovascular (Table 4). By 6 months, 39 deaths
(12.9%) had occurred among patients assigned
to placebo and 38 (12.5%) among those assigned
to OM.
Adverse event rates for SVT, VT, and myocardial
ischemia were similar in patients assigned to
placebo or OM (Table 4). Investigators reported
SVT adverse events in 20 (6.6%) patients in the
pooled placebo compared with 11 (3.6%) in the OM
TABLE 1 Continued
Pooled Cohort 1 Cohort 2 Cohort 3
Placebo
(n ¼ 303)
OM
(n ¼ 303)
Placebo
(b ¼ 103)
OM
(n ¼ 103)
Placebo
(n ¼ 99)
OM
(n ¼ 99)
Placebo
(n ¼ 101)
OM
(n ¼ 101)
Characteristics on presentation
Body mass index, kg/m2 29.1  5.9 29.1  5.9 28.4  5.1 30.1  6.6 29.5  6.8 28.5  5.8 29.4  5.8 28.7  5.1
Systolic BP, mm Hg 119  18* 117  17 115  18 118  18 119  19 116  17 123  17 117  15
Diastolic BP, mm Hg 72  11 71  11 71  10 71  10 71  12 72  12 73  12 70  10
Pulse rate, beats/min 78  13 78  13 79  13 78  13 78  12 79  13 79  13 78  14
Respiratory rate, breaths/min 21  5 22  4 22  5 22  4 22  4 22  4 21  4 22  4
O2 saturation 95  4 95  3 96  3 96  3 94  5 95  3 95  4 95  3
Dyspnea NRS (range 0–10)† 5.8  2.2 6.2  1.9 5.9  2.2 6.1  1.9 5.7  2.2 6.3  1.9 5.8  2.1 6.3  2.0
Troponin I, URL 0.04 ng/ml 0.044*
(0.023–
0.080)
0.054
(0.026–
0.095)
0.032
(0.017–
0.070)
0.060
(0.0712–
0.606)
0.051
(0.028–
0.079)
0.044
(0.030–
0.084)
0.047
(0.029-
0.085)
0.056
(0.026–
0.092)
NT-proBNP, pg/ml 9,026
(4,704–
16,208)
9,153
(4,432–
16,247)
8,450
(4,127–
16,890)
7,674
(3,721–
14,867)
10,856
(5,648–
17,009)
10,488
(5,610–
16,026)
8,721
(4,055–
14,174)
10,416
(4,763–
71,35)
eGFR, ml/min/1.73 m2 53  18* 52  18 53  19 52  18 49  17 53  19 56  17 50  18
Time from presentation to randomization 15.3  8.2* 14.3  8.8 13.7  7.8 11.8  7.6 16.3  8.2 15.8  9.7 15.9  8.3 15.2  8.7
Time from first diuretic dose to randomization 12.6  7.3* 12.0  7.5 10.9  7.1 10.3  7.3 13.4  7.4 13.1  7.7 13.6  7.3 12.6  7.3
Values are mean  SD, n (%), or median (interquartile range). *Denotes significant differences (p < 0.05) between individual placebo cohorts. †Smaller value indicates better dyspnea condition.
ACE ¼ angiotensin-converting enzyme; AF ¼ atrial fibrillation; AHF ¼ acute heart failure; BP ¼ blood pressure; eGFR ¼ estimated glomerular filtration rate; HF ¼ heart failure; LVEF ¼ left ventricular
ejection fraction; MI ¼ myocardial infarction; Nonwhite ¼ includes American-Indian or Alaska Native, Asian, Black or African-American, Native Hawaiian or Pacific Islander, Mixed Race or Other;
NRS ¼ numerical rating scale; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; NYHA ¼ New York Heart Association; OM ¼ omecamtiv mecarbil; URL ¼ upper reference limit.
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1449group, predominantly resulting from atrial fibrillation
or flutter, whereas reports of VTs were similar.
The CEC confirmed 3 (1.0%) post-randomization
myocardial infarctions in the placebo group
compared with 7 (2.3%) in the OM-treated cohorts
(Online Table 1).
Cardiac troponin I (cTnI) was intensively moni-
tored throughout the study with 4,750 samples cen-
trally analyzed at a blinded core laboratory. The
median baseline cTnI in the pooled OM groups was
0.054 ng/ml (interquartile range [IQR]: 0.026 to
0.095 ng/ml) compared with 0.044 ng/ml (IQR: 0.023
to 0.080 ng/ml) in the pooled placebo group. The
median change from baseline to end of study drug
infusion (48 h) was 0.000 ng/ml (IQR: 0.017 to 0.012
ng/ml) for the pooled OM group and 0.004 ng/ml
(IQR: 0.017 to 0.001 ng/ml) for the pooled placebo
group. Within cohort 3, the change from baseline
troponin in the high-dose OM group versus the cohort
3 placebo was 0.001 ng/ml (IQR: 0.011 to 0.021 ng/ml)
and 0.005 ng/ml (IQR: 0.015 to 0.001 ng/ml),
respectively. OM exposure (maximum concentration
[Figure 2] or C48h [Online Figures 5A and 5B]) did not
predict the maximum change from baseline in cTnI. In
similar analyses made on the basis of the 89 patients
in the PK/PD substudy, neither the maximal change in
SET nor the maximal change in LVESD predicted the
maximum change from baseline in cTnI (Online
Figures 6 and 7).DISCUSSION
In ATOMIC-AHF, a phase II dose-finding study, OM
did not improve the primary endpoint of dyspnea or
any pre-specified secondary outcome when compared
with placebo. However, there was a suggestion of
greater dyspnea relief in the high-dose OM cohort
compared with its concurrent placebo group, as
assessed by both Likert and numeric rating scales.
OM appeared generally well tolerated, with approxi-
mately dose-proportional PK properties associated
with prolonged ventricular systole and decreased
LVESD. Although OM-treated patients had a small
numeric excess of episodes of myocardial ischemia,
this difference was not temporally related to study
drug exposure. The small increases in plasma
troponin in patients assigned to OM had no apparent
relationship with OM plasma concentrations. There
was no increase in symptomatic hypotension or
arrhythmias in the OM-treated patients.
OM improves cardiac performance through a
novel mechanism of selectively activating cardiac
myosin (5). The PD signature of this mechanism of
action, prolongation of myocardial systole, has been
demonstrated in healthy volunteers (7) and in
patients with CHF (8). This same signature was
evident in patients with AHF in ATOMIC-AHF, and
the relationship between the OM plasma concentra-
tions and prolongation of the SET in ATOMIC-AHF
CENTRAL ILLUSTRATION ATOMIC-HF: Effect of OM on Dyspnea in Acute Heart Failure
Teerlink, J.R. et al. J Am Coll Cardiol. 2016; 67(12):1444–55.
Although omecamtiv mecarbil (OM) did not improve the primary endpoint of dyspnea relief when comparing the 3 OM dose groups with pooled placebo (A), OM did
improve dyspnea response in the patients receiving the highest dose when compared with the paired placebo groups (B). Columns represent the percentage of patients
with dyspnea relief at 48 h. *Ratio of response rate to pooled placebo. **Ratio of response rate to placebo within each cohort. ATOMIC-HF ¼ Acute Treatment with
Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure; CI ¼ confidence interval.
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TABLE 2 Secondary Endpoints
Secondary Endpoint
Pooled Placebo
(n ¼ 303)
Cohort 1 Cohort 2 Cohort 3
Placebo
(n ¼ 103)
OM
(n ¼ 103)
Placebo
(n ¼ 99)
OM
(n ¼ 99)
Placebo
(n ¼ 101)
OM
(n ¼ 101)
Dyspnea numerical
response AUC through
day 5*
3.5 (3.3–3.8) 3.6 (3.1–4.0) 3.5 (3.1–3.9) 3.2 (2.8–3.6) 3.6 (3.2–4.0) 3.8 (3.4–4.3) 3.7 (3.3–4.0);
p ¼ 0.038†
Patient global assessment
response
127 (41.9) 35 (34.0) 44 (42.7) 50 (50.5) 48 (48.5) 42 (41.6) 51 (50.5)
Death or worsening HF
within 7 days
52 (17.2) 25 (24.3) 13 (12.6);
p ¼ 0.027†
15 (15.2) 9 (9.1) 12 (11.9) 9 (8.9)
Length of initial hospital
stay; median days
(95% CI)
9 (8 to 9) 9 (8 to 10) 8 (7 to 9) 8 (7 to 9) 7 (7 to 8) 9 (9 to 11) 9 (8 to 10)
Days alive out of hospital
through 30 days;
median (95% CI)
22 (21 to 23) 22 (21 to 23) 22 (21 to 23) 23 (22 to 24) 23 (23 to 24) 21 (20 to 23) 22 (21 to 23)
NT-proBNP change from
baseline (pg/ml) at
48 h; median (95% CI)
1,805 (2,271
to 1,370)
1,602 (2,099
to 797)
2,076 (2,746
to 1,292)
1,987 (3,373
to 1,695)
2,161 (4,273
to 1,336)
1788 (2,805
to 890)
1742 (2,517
to 1,017)
Values are mean (95% CI) or n (%) unless otherwise indicated. *Smaller value indicates better dyspnea condition. Analysis of covariance model least square means (SE) for the 6
cohort/treatment arm, when compared within the same cohort, are 3.6 (0.2), 3.4 (0.2), 3.4 (0.2), 3.4 (0.2), 4.1 (0.2), 3.6 (0.2). †Nominal p value compared with matching
placebo from same cohort; all others nonsignificant.
AUC ¼ area under the curve; CI ¼ confidence interval; other abbreviations as in Table 1.
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1451was nearly identical to that seen in the previous 2
studies. These findings demonstrated that this
mechanism of action is operative in AHF and provides
evidence that this effect translated into a physiolog-
ical benefit with a significant reduction in LVESD, a
finding consistent with an improvement in cardiac
performance and related to improved long-term sur-
vival (12). Although SET is inversely related to heart
rate, it has also been long recognized that patients
with reduced cardiac output or EF have decreased
SETs (13), and thus OM may be viewed as effectively
normalizing ejection time.
The most common presenting symptom in patients
with AHF, dyspnea at rest or with minimal exertion,
remains a clinically meaningful endpoint (14). OMTABLE 3 Placebo-Corrected Change From Baseline in Selected Pharm
Placebo–Corrected Change
From Baseline in:
OM Plasma Con
$88 to 200 ng/ml >200 to 30
Heart rate, beats/min 0.1 (1.4 to 1.1) 2.0‡ (3.6
Systolic BP, mm Hg 0.3 (1.1 to 1.7) 0.6 (1.2
Systolic ejection time, ms 23.4§ (7.4 to 39.4) 33.6k (19.8
LV end-systolic dimension, cm 0.01 (0.4 to 0.4) 0.03 (0.4
LV end-diastolic dimension, cm 0.04 (0.4 to 0.3) 0.05 (0.2
LV fractional shortening, % 1.2 (5.0 to 2.6) 0.5 (2.5
LV stroke volume, ml¶ 5.5 (2.7 to 13.8) 4.8 (2.7
Values are mean placebo-corrected change from baseline (95% confidence interval). *
†Positive slope indicates increase in variable with respect to increasing OM plasma conce
outflow tract velocity time integral.
LV ¼ left ventricular; PK ¼ pharmacokinetics; other abbreviations as in Table 1.increased cardiac output and reduced LV filling
pressures in animal models (5,6), and it improved
cardiac function in humans (7,8), thereby providing a
mechanism for dyspnea relief in patients. Previous
trials suggested that selection of symptomatic
patients and objective signs of congestion early in
their hospital course provide the best opportunity to
demonstrate a clinical benefit on dyspnea (15,16). In
ATOMIC-AHF, dyspnea relief was evaluated by a
responder variable requiring early and sustained
improvement in dyspnea compared with standard
therapy without evidence of clinical worsening
within the first 48 h. In an attempt to increase the
power of this phase II study for a symptom endpoint,
the primary analysis pre-specified comparisonsacodynamic Variables
centration*
PK Slope† PK Slope p Value0 ng/ml >300 to 787 ng/ml
to 0.4) 2.3§ (3.9 to 0.6) 0.006 <0.0001
to 2.4) 2.4§ (0.6 to 4.2) 0.005 0.0017
to 47.4) 53.2k (38.0 to 68.3) 0.113 <0.0001
to 0.3) 0.23 (0.61 to 0.14) 0.001 0.047
to 0.3) 0.07 (0.4 to 0.2) 0.0004 0.25
to 3.4) 1.3 (2.1 to 4.7) 0.004 0.26
to 12.2) 6.3 (1.7 to 14.3) 0.014 0.10
Number of echocardiographic observations within concentration ranges ¼ 14 to 23.
ntrations. ‡p < 0.05. §p < 0.01. kp < 0.0001. ¶LV stroke volume on the basis of LV
FIGURE 1 Left Ventricular Systolic Ejection Times
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Systolic ejection time increased as corresponding plasma omecamtiv mecarbil
concentrations rose in 89 subjects from the echocardiographic substudy. Solid line ¼ linear
regression; dashed lines ¼ 95% confidence interval.
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1452among the pooled placebo group and the individual
OM dose cohorts. This endpoint was not met, perhaps
reflecting a failure of OM to improve dyspnea. How-
ever, major differences in the characteristics andTABLE 4 Adverse Events
Patient Incidence Pooled Placebo (n ¼
All AEs 191 (63.0)
3 most common AEs
Cardiac failure* 53 (17.5)
Hypokalemia 18 (5.9)
Hypotension 14 (4.6)
All serious AEs 70 (23.1)
3 most common serious AEs
Cardiac failure* 29 (9.6)
Acute renal failure 4 (1.3)
Hypotension 0 (0.0)
Deaths through 30 days 10 (3.3)
HF 9 (3.0)
Sudden cardiac death 1 (0.3)
MI 0 (0.0)
Other cardiovascular 0 (0.0)
AEs leading to discontinuation of investigational
product
15 (5.0)
Number of subjects reporting AEs of ischemic
heart disease, MI, increased troponins
5 (1.7)
Number of subjects reporting AEs of SVTs or VTs 34 (11.2)
SVTs 20 (6.6)
AF or atrial flutter 16 (5.3)
VTs 18 (5.9)
Values are n (%). *Cardiac failure includes both “Cardiac failure” and “Cardiac failure co
AE ¼ adverse event; SVT ¼ supraventricular tachyarrhythmia; VT ¼ ventricular tachyabehavior of the placebo group among the cohorts
undermined the validity of the pooled placebo group
as the comparator. The placebo response rate was
much higher than predicted (41% actual vs. 23% pre-
dicted), thus reducing the power of the trial to
observe a beneficial treatment effect. In addition,
patients were randomized, on average, 15 h after
presentation, a significantly longer period of time
than in a recent clinical trial (16), thereby potentially
limiting the ability to discern a treatment effect.
When the effect of high-dose OM was compared
with the matching placebo, a 14% absolute (41%
relative) treatment effect emerged at 48 h, which was
additionally supported by analyses suggesting a
relationship between OM dose, as well as plasma
concentrations, and dyspnea improvement. Patients
treated with OM in high-dose cohort 3 also had
improved dyspnea relief as measured by the numer-
ical rating scale over 5 days.
Increased troponins in patients admitted for AHF
(17) have been related to increased long-term mor-
tality rates in some studies (18–20), but not others
(21). Previous clinical studies demonstrated that the
dose-limiting toxicity of OM is provocation of
myocardial ischemia; thus, ATOMIC-AHF used
intensive sampling of cardiac troponin in all patients,303)
Pooled OM
(n ¼ 303)
Cohort 1 OM
(n ¼ 103)
Cohort 2 OM
(n ¼ 99)
Cohort 3 OM
(n ¼ 101)
177 (58.4) 73 (70.9) 49 (49.5) 55 (54.5)
46 (15.2) 17 (16.5) 14 (14.1) 15 (14.9)
20 (6.6) 7 (6.8) 7 (7.1) 6 (5.9)
24 (7.9) 14 (13.6) 5 (5.1) 5 (5.0)
66 (21.8) 24 (23.3) 24 (24.2) 18 (17.8)
26 (8.6) 8 (7.8) 11 (11.1) 7 (6.9)
6 (2.0) 2 (1.9) 2 (2.0) 2 (2.0)
3 (1.0) 3 (2.9) 0 (0.0) 0 (0.0)
8 (2.6) 1 (1.0) 4 (4.0) 3 (3.0)
4 (1.3) 0 (0.0) 2 (2.0) 2 (2.0)
2 (0.6) 1 (1.0) 1 (1.0) 0 (0.0)
1 (0.3) 0 (0.0) 0 (0.0) 1 (1.0)
1 (1.0) 0 (0.0) 0 (0.0) 1 (1.0)
15 (5.0) 7 (6.8) 4 (4.0) 4 (4.0)
9 (3.0) 2 (1.9) 2 (2.0) 5 (5.0)
26 (8.6) 13 (12.6) 5 (5.1) 8 (7.9)
11 (3.6) 6 (5.8) 0 (0.0) 5 (5.0)
7 (2.3) 3 (2.9) 0 (0.0) 4 (4.0)
16 (5.2) 8 (7.8) 5 (5.1) 3 (3.0)
ngestive” preferred terms.
rrhythmia; other abbreviations as in Table 1.
FIGURE 2 Maximal Troponin Concentrations
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Maximal concentrations (Cmax) of omecamtiv mecarbil in plasma did not predict maximal
change from baseline in troponin concentrations (range 40 to 100 ng/ml). The inset
presents the same data with an expanded y-axis (range 4 to 4 ng/ml) excluding outliers.
Solid circles ¼ 1 patient; lines in inset ¼ linear regression and 95% confidence intervals.
Max ¼ maximal.
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1453with additional sampling when there was any clinical
suspicion of ischemia. Consistent with other AHF
studies (19,21), baseline troponin was greater than the
99th percentile upper reference limit in more than
one-half the enrolled patients. An analysis of the
troponin change from baseline over time revealed a
slightly higher troponin concentration in patients
assigned to OM versus placebo at 48 h. In pooled data,
no relationship between OM exposure (either
maximum concentration or C48h) and the maximal
troponin increase from baseline was apparent. Addi-
tionally, analysis for the echocardiographic substudy
revealed no relationship between maximal change in
either SET or LVESD and the maximal change in
troponin. The absence of a discernible association of
OM exposure, its PD effect on SET, or one of its main
physiological effects (LVESD) with the small magni-
tude of the troponin change made it difficult to draw
definitive conclusions about the clinical significance
of these troponin findings. Whereas most studies
have demonstrated that OM inhibits non–actin-
dependent cardiac myosin adenosine triphosphatase
(5,22) and does not increase myocardial oxygen con-
sumption (6), a recent study in anesthetized animals
suggested OM-related increased myocardial oxygen
consumption (23). Although methodological limita-
tions undermined this study (24), these data, com-
bined with the small numeric increase in the
incidence of myocardial infarction, support the need
to continue assessing whether OM contributes to
myocardial injury.
Currently available inotropes have demonstrated
proarrhythmic effects linked to increased mortality.
Dobutamine, dopamine, milrinone, and levosimendan
all havewell-recognized adverse effects of tachycardia
that can limit their clinical utility. In the OPTIME-HF
(Organized Program to Initiate Life-saving Treatment
in Hospitalized Patients With Heart Failure) trial,
patients treated with milrinone had a >2-fold risk of
developing VT or atrial fibrillation and a 3-fold risk of
developing new atrial fibrillation or atrial flutter dur-
ing the index hospitalization (25). In REVIVE II (Ran-
domized Multicenter Evaluation of Intravenous
Levosimendan Efficacy), levosimendan treatment
increased heart rate by 2 to 8 beats/min, remaining
statistically significant for at least 5 days, and was
associated with a 50% increase in VT and a 4-fold
increase in ventricular extrasystoles and atrial fibril-
lation compared with placebo (26). These proar-
rhythmic effects are inextricably linked to these
agents’ mechanisms of action, which increase
contractility through increased intracellular cyclic
adenosine monophosphate and calcium. As a cardiac
myosin activator, OM does not increase theseintracellular signals and effectors (5), and it had no
evidence of increased arrhythmogenicity in previous
clinical studies (7,8). In ATOMIC-AHF, OM decreased
heart rate versus placebo and did not increase risk of
SVT or VT. OM improved left atrial function and
reduced volumes in healthy volunteers; such an effect
could reduce the propensity to atrial arrhythmias (7).
Worsening HF during initial hospitalization has
emerged as a clinically important event with
both short- and long-term prognostic implications
(19,27–29). In ATOMIC-AHF, too few events occurred
to evaluate this endpoint meaningfully, although
there were numerically fewer worsening HF events
among patients who received OM than in patients
who received placebo within each cohort. Both mil-
rinone (25) and levosimendan (26) have been associ-
ated with increases in mortality; in the current study,
180-day all-cause mortality was 12.9% in the placebo
and 12.5% in the OM group. More data are required to
assess differences in mortality.
STUDY LIMITATIONS. ATOMIC-AHF was a phase II,
dose-finding study that was underpowered to assess
the potential impact of OM on clinical outcomes. In
addition, the serial enrollment of the cohorts sepa-
rated by months resulted in differences in the patient
populations and placebo response rates among the
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Available interventions that increase myocardial
contractile function in patients with HF and reduced
LVEF have safety liabilities including increased oxygen
requirements, hypotension, heart rate acceleration,
arrhythmias, and increased mortality. Treatment with
the selective cardiac myosin activator OM increased
SET and at high dose seemed to improve dyspnea
without the foregoing adverse effects in patients with
AHF, but there were small increases in serum troponin
levels.
TRANSLATIONAL OUTLOOK: Further studies are
needed to evaluate the safety and efficacy of an oral
preparation of OM in a larger group of patients with
HF and reduced EF.
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1454cohorts, thereby confounding the comparisons of the
pooled placebo cohort with the individual OM cohorts.
CONCLUSIONS
In patients with AHF, IV OM did not meet the
primary endpoint of dyspnea improvement, but it
was generally well tolerated, it increased SET, and
it may have improved dyspnea in the high-dose
group. ATOMIC-AHF provides the basis for addi-
tional investigation of IV OM in patients with
decompensated HF, as well as the development of
oral OM for the treatment of patients with CHF, as has
been recently explored in the COSMIC-HF study
(NCT01786512).
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